Mouse Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) CLIA Kit
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Mouse Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) Chemiluminescent Immunoassay (CLIA) Kit is a Chemiluminescent Immunoassay (CLIA) kit against Cyclin Dependent Kinase Inhibitor 1B (CDKN1B).
Documents del producto
Product specifications
| Category | CLIA Kits |
| Immunogen Target | Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) |
| Reactivity | Mouse |
| Detection Method | Chemiluminescent |
| Assay Data | Quantitative |
| Test Range | 3.13 pg/ml - 200 pg/ml |
| Sensitivity | 1.88 pg/ml |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 96 tests |
| Form | Lyophilized |
| Tested Applications | CLIA |
| Sample Type | Serum, plasma and other biological fluids. |
| Availability | Shipped within 5-12 working days. |
| Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
| Dry Ice | No |
| Background | CLIA Kits CDKN1B |
| Status | RUO |
| Note | The validity for this kit is 6 months. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
Related Products
Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
CDKN1B antibody
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Ver Producto